Keensight-backed Symeres snaps up Exemplify BioPharma

Exemplify BioPharma is Symeres’ second acquisition in the US this year.

  • Keensight Capital acquired Symeres in 2021
  • Exemplify BioPharma provides integrated small molecule chemistry manufacturing and controls services to pharmaceutical and biotech partners
  • Symeres is a transatlantic small molecule contract research and manufacturing organisation

Symeres, a Keensight Capital portfolio company, announced the acquisition of Exemplify BioPharma, a provider of integrated end-to-end CMC drug development deliverables to pharmaceutical and biotech firms.

Exemplify, based in Cranbury, New Jersey, offers consultancy services in process chemistry, analytical chemistry and formulation development. The company will remain under the management of co-founders Yadan Chen, CEO, and Paul O’Shea, chief scientific officer.

The acquisition extends the Nijmegen, Netherlands-based Symeres’ foothold in the US, where the company generates approximately 50 percent of its revenues. Symeres is a global drug discovery contract research organisation and contract development and manufacturing organisation.

Exemplify BioPharma is Symeres’ second acquisition in the US this year, following the acquisition of Organix.

“The addition of Exemplify BioPharma in New Jersey marks another milestone in Symeres’ strategy to build a truly transatlantic business, serving the biopharma industry globally,” said Amit Karna, partner at Keensight Capital. “The scientific and cultural fit of Exemplify BioPharma within the group is excellent. Keensight Capital is delighted to support Symeres in this exciting acquisition.”